Metabolic Burden and Response to Repeated Intranasal Esketamine in Treatment-Resistant Depression: A Longitudinal Multidomain Biomarker Study
Research Square September 7, 2026 Jennifer L Phillips, Ifeoluwa Olaoluwa, Areebah Ahmed et al. preprint
Abstract Metabolic, inflammatory, and neurotrophic measures may provide complementary insight into biological heterogeneity underlying treatment-resistant depression and response to ketamine-based treatments. However, biomarker studies of ketamine treatment have focused on individual markers or biological domains, most commonly inflammatory or neurotrophic, while metabolic measures remain...